Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

FreeOx Biotech Celebrates Landmark 2024 with Record Growth: New Hires, Groundbreaking Trial Selections, and Major Funding Milestones


News provided by

FreeOx Biotech

Feb 13, 2025, 09:00 ET

Share this article

Share toX

Share this article

Share toX

FreeOx Biotech
FreeOx Biotech

Innovative Biotech Company Expands Executive Team with Three C-Suite Appointments and Advances Pipeline with Key Trial Evaluations

BARCELONA and PALO ALTO, Feb. 13, 2025 /PRNewswire-PRWeb/ -- FreeOx Biotech, a clinical-stage biopharmaceutical company pioneering a novel drug class for Acute Ischemic Stroke (AIS), announced significant progress in 2024, driven by cutting-edge clinical advancements, strategic investments, and key executive appointments.

Highlights of 2024, positioning FreeOx for growth and innovation:

FreeOx Biotech, a clinical-stage biopharmaceutical company pioneering a novel drug class for Acute Ischemic Stroke (AIS), announced significant progress in 2024, driven by cutting-edge clinical advancements, strategic investments, and key executive appointments.

Post this
  • Clinical Milestones: After a rigorous 5-year process, FreeOx's lead compound, Ox-01, was the only and first drug ever selected by the National Institute of Neurological Disorders and Stroke (NINDS) for evaluation on its STEP (StrokeNet Thrombectomy Endovascular Platform) clinical platform.
  • IP: The company filed a composition of matter patent for a proprietary uric acid co-crystal.
  • Strategic Investment: FreeOx received capital investment from Neuro Technology Investors (NTI).
  • Executive Appointments: Strengthening its leadership, Dr. Ian Hitchcock joined as Chief Development Officer, Pat Nasshorn as Chief Business Development Officer, and Dr. Jina Swartz as Chief Medical Officer

Emmett-Phil Coriat, CEO of FreeOx Biotech, commented, "I am thrilled to welcome the new management team and these appointments bring invaluable expertise in drug development, strategic partnerships, and neuroscience to FreeOx. Their leadership will be crucial as we advance our mission to develop innovative therapies for AIS and other critical unmet medical needs."

Dr. Ian Hitchcock brings 25 years of experience in the pharmaceutical and biotech industries, with global expertise spanning development, clinical research, and executive leadership. He has held senior roles at Abbott, Bristol-Myers Squibb, Pharmion/Celgene in the US, and Aimmune, among others. Dr. Hitchcock earned his MBChB from the University of Cape Town, where he partnered in building South Africa's largest private primary healthcare service. He later served as a Clinical Fellow in Virology and HIV in London before transitioning fully into the pharmaceutical sector in 1999 while also maintaining an NHS clinical role until 2006.

Ian Hitchcock added, "I am delighted to join the FreeOx Biotech team and leverage my expertise across multiple functions and global territories in the industry, including drug development and clinical strategy, to advance the company's transformative pipeline, with a particular interest in bringing innovative and first-in-class products to patients in areas of high unmet medical needs. FreeOx Biotech's commitment to addressing unmet medical needs through innovative therapies is truly inspiring, and I look forward to contributing to the company's strategic initiatives and partnerships."

Pat Nasshorn, an accomplished business development leader, also joins FreeOx Biotech with a wealth of experience in the healthcare industry. Her career includes executive roles at Merck, Johnson & Johnson, and Bristol-Myers Squibb, followed by a decade as a business development executive at Care Capital, LLC. Most recently, she worked as a consultant, forging strategic partnerships for multiple pharmaceutical companies.

Commenting on her new role, Nasshorn said, "The company's innovative approach to addressing Acute Ischemic Stroke presents a tremendous opportunity to make a meaningful impact in patient care," said Nasshorn. "I am excited to join FreeOx Biotech at this critical juncture and look forward to leveraging my extensive network and experience to drive strategic partnerships and accelerate the company's growth."

Dr. Jina Swartz, a seasoned expert in neurology and neuroscience drug development, rounds out the new executive team. With over 30 years of experience in academic neurology and global clinical development, including roles at Merck, Takeda, Eisai, and GSK, Dr. Swartz brings unmatched expertise in exploratory research and late-stage clinical programs.

Recently elected as a Fellow of the Academy of Medical Sciences, Dr. Swartz said, "I'm pleased to be joining FreeOx Biotech at this important time for the company, as they embark upon investigating the efficacy of Ox-01 in the NINDS' new stroke-dedicated STEP clinical platform. The prospect of joining a dedicated team driving forward a novel therapeutic approach for effectively treating patients with Acute Ischemic Stroke, a common, debilitating disorder in which so many failures have resulted in development slowing almost to a halt, is a unique opportunity that I look forward to embracing".

About FreeOx Biotech:

FreeOx Biotech is a clinical-stage biopharmaceutical company dedicated to developing Cerebrovascular Protective Therapy, a new drug class for the emergency treatment of Acute Ischemic Stroke (AIS) patients. By focusing on restoring microcirculation homeostasis and enhancing penumbra reperfusion thereby salvaging recoverable brain tissue, FreeOx Biotech aims to revolutionize stroke care and improve patient outcomes. FreeOx' s Ox-01, based on a proprietary co-crystal of uric acid with composition of matter protection, is in development as an emergency Adjunct Mechanical Thrombectomy Therapy for Acute Ischemic Stroke (AIS.). FreeOx is building a pipeline based on another proprietary liposomal formulation technology that broadly expands opportunities in neurology. Founded by Dr. Ángel Chamorro, MD, a leading stroke neurologist and pioneer in the use of Uric Acid as an emergency treatment for AIS, FreeOx 's novel adjunct drug has been shown to reperfuse the brain microcirculation. By contrast, current emergency AIS treatments are effective only in addressing recanalization (macrocirculation restoration).

Media contact:

Ali Nagy

[email protected]

Media Contact

Ali Nagy, FreeOx Biotech, 1 714-310-4439, [email protected], https://freeoxbiotech.com/

SOURCE FreeOx Biotech

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.